Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis

AIM: Leflunomide, via its active metabolite teriflunomide, is used in rheumatoid arthritis (RA) treatment, yet approximately 20 to 40% of patients cease due to toxicity. The aim was to develop a time‐to‐event model describing leflunomide cessation due to toxicity within a clinical cohort and to inve...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Hopkins, Ashley M., Wiese, Michael D., Proudman, Susanna M., O'Doherty, Catherine E., Upton, Richard N., Foster, David J. R.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2015
Assuntos:
Pharmacogenetics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4693574/
https://ncbi.nlm.nih.gov/pubmed/26331989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12760
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados